o
o
Sažetak
o
Reference
[2]Gaba P, Gersh BJ, Muller J,et al . Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research[J]. Nat Rev Cardiol. 2023 ，20(3):181-196.
[3]Kurochkina ON. [Features of chronic kidney disease in elderly patients.]. Adv Gerontol. 2020，33(1):113-120.
[4]Sarkar G, Gaikwad VB, Sharma A,et al . Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study[J]. Adv Ther. 2022 ,39(2):923-942.
[5]Xiao SQ, Ibarra F Jr, Cruz M. Intravenous Metoprolol Versus Diltiazem for Rate Control in Atrial Fibrillation[J]. Ann Pharmacother. 2022 ,56(8):916-921.
[6]He Y, Jiang H, Du K, et al. Exploring the mechanism of Taohong Siwu Decoction on the treatment of blood deficiency and blood stasis syndrome by gut microbiota combined with metabolomics[J]. Chinese Medicine, 2023, 18(1):44-62.
[7]Jiang S. Observation on the Effectiveness and Prognosis of Traditional Chinese Medicine Syndrome Differentiation Treatment for Bi Syndrome[J]. MEDS Chinese Medicine, 2023, 5(5):57-64.
[8]Li YY, Li JJ, Ge FX, et al. [Research progress on in vitro models of cardiomyocyte injury][J]. Zhongguo Zhong Yao Za Zhi. 2021,46(13):3257-3269.
[9]Wen M, Liang Y, Shen Q,et al . Effects of Teaching Resourcefulness in Patients with Coronary Heart Disease[J]. West J Nurs Res. 2022 ,44(9):874-885.
[10]Jurisch D, Laufs U. Chronisches Koronarsyndrom : Neuklassifikation der stabilen koronaren Herzkrankheit [Chronic coronary syndrome : New classification of stable coronary artery disease][J]. Internist (Berl). 2021 ,62(1):47-57.
[11]Feng C, Chen F, Li L,et al. Traditional Chinese Medicine for Patients of Coronary Artery Disease: Savior or Troublemaker? A Cohort Study About the Adherence to Antiplatelet Therapy[J]. J Gen Intern Med. 2022 ,37(4):981-983.
[12]Yuan G, Han A, Wu J,et al. Bao Yuan decoction and Tao Hong Si Wu decoction improve lung structural remodeling in a rat model of myocardial infarction: Possible involvement of suppression of inflammation and fibrosis and regulation of the TGF-β1/Smad3 and NF-κB pathways[J]. Biosci Trends. 2018;12(5):491-501.
[13]Liang X, Wang Q, Jiang Z,et al. Clinical research linking Traditional Chinese Medicine constitution types with diseases: a literature review of 1639 observational studies[J]. J Tradit Chin Med. 2020 ,40(4):690-702.
[14]Ji Z, Hu H, Qiang X, et al. Traditional Chinese Medicine for COVID-19: A Network Meta-Analysis and Systematic Review. Am J Chin Med. 2022,50(4):883-925.
[15]Fengli S, Jianfeng Z, Zhihan G, et al. Traditional Chinese Medicine Syndrome Types Among Single-Syndrome Bipolar Mania Cases Described in Chinese Literature[J]. Altern Ther Health Med. 2022,28(2):40-43.
[16]Zhang X, Li Z, Shen C, et al. Tao-Hong-Si-Wu decoction improves depressive symptoms in model rats via amelioration of BDNF-CREB-arginase I axis disorders[J]. Pharmaceutical Biology, 2022, 60(1):1739-1750.
[17]Zheng S, Xue T, Wang B,et al. Chinese Medicine in the Treatment of Ulcerative Colitis: The Mechanisms of Signaling Pathway Regulations[J]. Am J Chin Med. 2022,50(7):1781-1798.
[18]Yang Q, Xie L, Zhang W,et al. Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019[J]. J Clin Pharm Ther. 2020 ,45(4):609-616.
[19]Myhre PL, Vaduganathan M, Claggett BL, et al. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction[J]. JACC Heart Fail. 2022,10(12):902-913.
[20]Maldonado-Ruiz R, Trujillo-Villarreal LA, Montalvo-Martínez L,et al . MCP-1 Signaling Disrupts Social Behavior by Modulating Brain Volumetric Changes and Microglia Morphology[J]. Mol Neurobiol. 2022 ,59(2):932-949.
[21]Wu Y, Li Z, Du B,et al . Different Associations of Systolic Blood Pressure and Body Mass Index With Cardiac Structure and Function in Young Children[J]. Hypertension. 2022 ,79(11):2583-2592.
Sva prava zadržana (c) 2025 Zhancheng Wang
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.